An observational study in Primary Sclerosing Cholangitis, sponsored by Gilead Sciences. Completed at 5 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-02-09.
Sponsored by Gilead Sciences · Observational
The objectives of this qualitative study are to elicit concepts about symptoms that are important to patients with primary sclerosing cholangitis (PSC), as well as the key impacts of symptoms on patients' day-to-day functioning.
In Step I, concept elicitation one-on-one interviews (via telephone or in person) will be conducted. The aims of the concept elicitation interviews are to:
An instrument will be developed based on the symptoms reported and in Step II of the study, the performance of the instrument will be assessed with further interviews.
228 studies on the registry are indexed under Cholangitis; 32 are open to participants now.
This study's enrollment of 26 is below the median of 140 across 65 observational studies indexed under Cholangitis.
Browse Cholangitis studies →Gilead Sciences is the lead sponsor of 680 studies on the registry; 24 are open to participants now.
Of its 259 completed or terminated interventional studies of FDA-regulated products, 249 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Participants will be recruited from approximately 5 clinical sites based in the United States.
Exclusion Criteria:
Approximately 20 participants will be included.
Approximately 30 participants will be included.
List Primary Sclerosing Cholangitis (PSC) Symptoms for inclusion in patient questionnaire
Interview participants to generate a list of the most common symptoms, as well as the most important symptoms, experienced by patients with PSC, and whether each symptom impacts day-to-day functioning.
Time frame: Up to 12 months
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gilead Sciences